KAI-4169, an intravenous (IV) formulation used in the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease-mineral and bone disorder (CKD-MBD), is in Phase 2 clinical testing.
As per the agreement, Ono receives rights to all indications for injectable formulations of KAI-4169 in Japan and also retains marketing rights in all other regions.
KAI will receive $13m as an upfront payment from Ono and will also receive a royalty on sales.
KAI Pharmaceuticals president and CEO Steven James said they are excited about the continued momentum of the KAI-4169 program, and they anticipate completing the Phase 2 trial and reporting data by the end of this year.